Accéder au contenu
Merck
Toutes les photos(1)

Documents

B7273

Sigma-Aldrich

Bezafibrate

≥98%, solid

Synonyme(s) :

2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C19H20ClNO4
Numéro CAS:
Poids moléculaire :
361.82
Numéro CE :
Numéro MDL:
Code UNSPSC :
12352200
ID de substance PubChem :
Nomenclature NACRES :
NA.77

Pureté

≥98%

Forme

solid

Solubilité

DMF: soluble
deionized water: insoluble
methanol: soluble

Auteur

Roche

Chaîne SMILES 

CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O

InChI

1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)

Clé InChI

IIBYAHWJQTYFKB-UHFFFAOYSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Application

Bezafibrate has been used:
  • a supplement in the standard diet (SD) for mice to study its effect on diabetes
  • to evaluate its effect on hepatitis C virus (HCV) assembly and secretion
  • to evaluate its effect on gonadal steroidogenesis and spermatogenesis of zebrafish and also used as standard for HPLC

Actions biochimiques/physiologiques

Bezafibrate has the ability to repress HCV assembly and secretion. It is used to treat dyslipidemia.
The peroxisome proliferator-activated receptor (PPAR) is a member of the steroid nuclear receptor superfamily. Bezafibrate is a peroxisome proliferator-activated receptor agonist for PPARα, PPARδ, and PPARγ. Lipoprotein lipase (LPL) activator.
PPARgamma agonists, including Bezafibrate, have beneficial effects in the suppression of the inflammatory response during RSV infection and therefore might have clinical efficacy in the course of severe RSV-infection.

Caractéristiques et avantages

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

Exclamation mark

Mention d'avertissement

Warning

Mentions de danger

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Bezafibrate improves insulin sensitivity and metabolic flexibility in STZ-induced diabetic mice
Franko A, et al.
Diabetes, 65(9), 2540-2552 (2016)
Akira Honda et al.
Hepatology (Baltimore, Md.), 57(5), 1931-1941 (2012-08-23)
Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator-activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC)
Bezafibrate, a lipid-lowering pharmaceutical, as a potential endocrine disruptor in male zebrafish (Danio rerio)
Velasco-Santamaria YM, et al.
Aquatic Toxicology (Amsterdam, Netherlands), 105(1-2), 107-118 (2011)
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice
Franko A, et al.
Molecular Metabolism, 6(3), 256-266 (2017)
Marc Engelen et al.
PloS one, 7(7), e41013-e41013 (2012-08-23)
X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene and is characterized by impaired beta-oxidation of very-long-chain fatty acids (VLCFA) and subsequent VLCFA accumulation in tissues. In adulthood X-ALD most commonly manifests as a gradually progressive myelopathy, (adrenomyeloneuropathy;

Articles

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique